AhR expression is increased in hepatocellular carcinoma

Journal of Molecular Histology

Volumn 44, Issue 4, 2013, Pages 455-461

  Liu, Ziyu ^a   Wu, Xing'An ^a   Zhang, Fanglin ^a   Han, Lurong ^b   Bao, Guoqiang ^c   He, Xianli ^c   Xu, Zhikai ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b The 323rd Hospital of PLA   (China)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

AhR; Hepatocellular carcinoma; Immunohistochemistry; Tissue microarray

Indexed keywords

AROMATIC HYDROCARBON RECEPTOR;

ADULT; ARTICLE; CANCER CELL; CANCER GRADING; CANCER STAGING; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY; TUMOR INVASION; WESTERN BLOTTING;

AGED; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; FEMALE; HUMANS; LIVER; LIVER NEOPLASMS; MALE; MIDDLE AGED; RECEPTORS, ARYL HYDROCARBON; STAINING AND LABELING;

EID: 84880877262     PISSN: 15672379     EISSN: 15672387     Source Type: Journal    
DOI: 10.1007/s10735-013-9495-6     Document Type: Article

References (46)

1. Abdelrahim M, Smith R 3rd, Safe S (2003) Aryl hydrocarbon receptor gene silencing with small inhibitory RNA differentially modulates Ah-responsiveness in MCF-7 and HepG2 cancer cells. Mol Pharmacol 63(6):1373-1381. doi: 10.1124/mol.63.6.1373 (Pubitemid 36627233)
2. Aleem E, Nehrbass D, Klimek F, Mayer D, Bannasch P (2011) Upregulation of the insulin receptor and type I insulin-like growth factor receptor are early events in hepatocarcinogenesis. Toxicol Pathol 39(3):524-543. doi: 10.1177/0192623310396905
3. Borlak J, Jenke HS (2008) Cross-talk between aryl hydrocarbon receptor and mitogen-activated protein kinase signaling pathway in liver cancer through c-raf transcriptional regulation. Mol Cancer Res 6(8):1326-1336. doi: 10.1158/1541-7786.MCR-08-0042
4. Brauze D, Rawluszko AA (2012) The effect of aryl hydrocarbon receptor ligands on the expression of polymerase (DNA directed) kappa (Polkappa), polymerase RNA II (DNA directed) polypeptide A (PolR2a), CYP1B1 and CYP1A1 genes in rat liver. Environ Toxicol Pharmacol 34(3):819-825. doi: 10.1016/j.etap.2012.09.004
5. Brooks SC 3rd, Brooks JS, Lee WH, Lee MG, Kim SG (2009) Therapeutic potential of dithiolethiones for hepatic diseases. Pharmacol Ther 124(1):31-43. doi: 10.1016/j.pharmthera.2009.06.006
6. Bui LC, Tomkiewicz C, Chevallier A, Pierre S, Bats AS, Mota S, Raingeaud J, Pierre J, Diry M, Transy C, Garlatti M, Barouki R, Coumoul X (2009) Nedd9/Hef1/Cas-L mediates the effects of environmental pollutants on cell migration and plasticity. Oncogene 28(41):3642-3651. doi: 10.1038/onc.2009.224
7. Callero MA, Suarez GV, Luzzani G, Itkin B, Nguyen B, Loaiza-Perez AI (2012) Aryl hydrocarbon receptor activation by aminoflavone: new molecular target for renal cancer treatment. Int J Oncol 41(1):125-134. doi: 10.3892/ijo.2012.1427
8. Celius T, Matthews J (2010) Functional analysis of six human aryl hydrocarbon receptor variants in human breast cancer and mouse hepatoma cell lines. Toxicology 277(1-3):59-65. doi: 10.1016/j.tox.2010.08.015
9. Denison MS, Pandini A, Nagy SR, Baldwin EP, Bonati L (2002) Ligand binding and activation of the Ah receptor. Chem Biol Interact 141(1-2):3-24 (Pubitemid 35229988)
10. Fan Y, Boivin GP, Knudsen ES, Nebert DW, Xia Y, Puga A (2010) The aryl hydrocarbon receptor functions as a tumor suppressor of liver carcinogenesis. Cancer Res 70(1):212-220. doi: 10.1158/0008-5472.CAN-09-3090
11. Fan R, Chen P, Zhao D, Tong JL, Li J, Liu F (2011a) Cooperation of deregulated Notch signaling and Ras pathway in human hepatocarcinogenesis. J Mol Histol 42(5):473-481. doi: 10.1007/s10735-011-9353-3
12. Fan RH, Li J, Wu N, Chen PS (2011b) Late SV40 factor: a key mediator of Notch signaling in human hepatocarcinogenesis. World J Gastroenterol 17(29):3420-3430. doi: 10.3748/wjg.v17.i29.3420
13. Fardel O (2013) Cytokines as molecular targets for aryl hydrocarbon receptor ligands: implications for toxicity and xenobiotic detoxification. Expert Opin Drug Metab Toxicol 9(2):141-152. doi: 10.1517/17425255.2013.738194
14. Fritz WA, Lin TM, Safe S, Moore RW, Peterson RE (2009) The selective aryl hydrocarbon receptor modulator 6-methyl-1, 3, 8-trichlorodibenzofuran inhibits prostate tumor metastasis in TRAMP mice. Biochem Pharmacol 77(7):1151-1160. doi: 10.1016/j.bcp.2008.12.015
15. Gramatzki D, Pantazis G, Schittenhelm J, Tabatabai G, Kohle C, Wick W, Schwarz M, Weller M, Tritschler I (2009) Aryl hydrocarbon receptor inhibition downregulates the TGF-beta/Smad pathway in human glioblastoma cells. Oncogene 28(28):2593-2605. doi: 10.1038/onc.2009.104
16. He J, Lee JH, Febbraio M, Xie W (2011) The emerging roles of fatty acid translocase/CD36 and the aryl hydrocarbon receptor in fatty liver disease. Exp Biol Med (Maywood) 236(10):1116-1121. doi: 10.1258/ebm.2011.011128
17. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61(2):69-90. doi: 10.3322/caac.20107
18. Jiang R, Xia Y, Li J, Deng L, Zhao L, Shi J, Wang X, Sun B (2010a) High expression levels of IKKalpha and IKKbeta are necessary for the malignant properties of liver cancer. Int J Cancer 126(5):1263-1274. doi: 10.1002/ijc.24854
19. Jiang YZ, Wang K, Fang R, Zheng J (2010b) Expression of aryl hydrocarbon receptor in human placentas and fetal tissues. J Histochem Cytochem 58(8):679-685. doi: 10.1369/jhc.2010.955955
20. Kakehashi A, Ishii N, Shibata T, Wei M, Okazaki E, Tachibana T, Fukushima S, Wanibuchi H (2011) Mitochondrial prohibitins and septin 9 are implicated in the onset of rat hepatocarcinogenesis. Toxicol Sci 119(1):61-72. doi: 10.1093/toxsci/kfq307
21. Kamenickova A, Dvorak Z (2012) Effects of flavored mineral waters on AhR-CYP1A1 signaling pathway in primary human hepatocytes and in human hepatic and intestinal cancer cells. Food Chem Toxicol 50(6):1933-1939. doi: 10.1016/j.fct.2012.03.073
22. Kawajiri K, Kobayashi Y, Ohtake F, Ikuta T, Matsushima Y, Mimura J, Pettersson S, Pollenz RS, Sakaki T, Hirokawa T, Akiyama T, Kurosumi M, Poellinger L, Kato S, Fujii-Kuriyama Y (2009) Aryl hydrocarbon receptor suppresses intestinal carcinogenesis in ApcMin/+ mice with natural ligands. Proc Natl Acad Sci USA 106(32):13481-13486. doi: 10.1073/pnas.0902132106
23. Kopf PG, Walker MK (2010) 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin increases reactive oxygen species production in human endothelial cells via induction of cytochrome P4501A1. Toxicol Appl Pharmacol 245(1):91-99. doi: 10.1016/j.taap.2010.02.007
24. Korashy HM, El Gendy MA, Alhaider AA, El-Kadi AO (2012) Camel milk modulates the expression of aryl hydrocarbon receptor-regulated genes, Cyp1a1, Nqo1, and Gsta1, in murine hepatoma Hepa 1c1c7 cells. J Biomed Biotechnol 2012:782642. doi: 10.1155/2012/782642
25. Llovet JM, Wurmbach E (2004) Gene expression profiles in hepatocellular carcinoma: not yet there. J Hepatol 41(2):336-339. doi: 10.1016/j.jhep.2004.06. 002 (Pubitemid 39177641)
26. Monteleone I, MacDonald TT, Pallone F, Monteleone G (2012) The aryl hydrocarbon receptor in inflammatory bowel disease: linking the environment to disease pathogenesis. Curr Opin Gastroenterol 28(4):310-313. doi: 10.1097/MOG.0b013e328352ad69
27. Morris SM, Baek JY, Koszarek A, Kanngurn S, Knoblaugh SE, Grady WM (2012) Transforming growth factor-beta signaling promotes hepatocarcinogenesis induced by p53 loss. Hepatology 55(1):121-131. doi: 10.1002/hep.24653
28. Narayanan GA, Murray IA, Krishnegowda G, Amin S, Perdew GH (2012) Selective aryl hydrocarbon receptor modulator-mediated repression of CD55 expression induced by cytokine exposure. J Pharmacol Exp Ther 342(2):345-355. doi: 10.1124/jpet.112.193482
29. Opitz CA, Litzenburger UM, Sahm F, Ott M, Tritschler I, Trump S, Schumacher T, Jestaedt L, Schrenk D, Weller M, Jugold M, Guillemin GJ, Miller CL, Lutz C, Radlwimmer B, Lehmann I, von Deimling A, Wick W, Platten M (2011) An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature 478(7368):197-203. doi: 10.1038/nature10491
30. Papatheodoridis GV, Lampertico P, Manolakopoulos S, Lok A (2010) Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J Hepatol 53(2):348-356. doi: 10.1016/j.jhep.2010.02.035
31. Peng TL, Chen J, Mao W, Liu X, Tao Y, Chen LZ, Chen MH (2009) Potential therapeutic significance of increased expression of aryl hydrocarbon receptor in human gastric cancer. World J Gastroenterol 15(14):1719-1729
32. Platten M, Opitz C, Wick W (2012) The aryl hydrocarbon receptor as a promoter of malignant glioma. Cell Cycle 11(4):643-644. doi: 10.4161/cc.11.4.19357
33. Schlezinger JJ, Liu D, Farago M, Seldin DC, Belguise K, Sonenshein GE, Sherr DH (2006) A role for the aryl hydrocarbon receptor in mammary gland tumorigenesis. Biol Chem 387(9):1175-1187. doi: 10.1515/BC.2006.145 (Pubitemid 44402063)
34. Schreiber S, Rignall B, Braeuning A, Marx-Stoelting P, Ott T, Buchmann A, Hammad S, Hengstler JG, Schwarz M, Kohle C (2011) Phenotype of single hepatocytes expressing an activated version of beta-catenin in liver of transgenic mice. J Mol Histol 42(5):393-400. doi: 10.1007/s10735-011-9342-6
35. Spink BC, Bennett JA, Lostritto N, Cole JR, Spink DC (2012) Expression of the aryl hydrocarbon receptor is not required for the proliferation, migration, invasion, or estrogen-dependent tumorigenesis of MCF-7 breast cancer cells. Mol Carcinog. doi: 10.1002/mc.21889
36. Su JM, Lin P, Wang CK, Chang H (2009) Overexpression of cytochrome P450 1B1 in advanced non-small cell lung cancer: a potential therapeutic target. Anticancer Res 29(2):509-515
37. Suzuki S, Pitchakarn P, Takeshita K, Asamoto M, Takahashi S, Sato S, Shirai T (2011) Roles for rat hepatocyte malignant transforming factor (HMTF) in late stage of hepatocarcinogenesis. Toxicol Pathol 39(7):1084-1090. doi: 10.1177/0192623311422077
38. Wang JH, Wang CC, Hung CH, Chen CL, Lu SN (2012a) Survival comparison between surgical resection and radiofrequency ablation for patients in BCLC very early/early stage hepatocellular carcinoma. J Hepatol 56(2):412-418. doi: 10.1016/j.jhep.2011.05.020
39. Wang Y, Li J, Chen J, Liu L, Peng Z, Ding J, Ding K (2012b) From cirrhosis to hepatocellular carcinoma in HCV-infected patients: genes involved in tumor progression. Eur Rev Med Pharmacol Sci 16(8):995-1000
40. Xie G, Peng Z, Raufman JP (2012a) Src-mediated aryl hydrocarbon and epidermal growth factor receptor cross talk stimulates colon cancer cell proliferation. Am J Physiol Gastrointest Liver Physiol 302(9):G1006-G1015. doi: 10.1152/ajpgi.00427.2011
41. Xie XL, Wei M, Kakehashi A, Yamano S, Tajiri M, Wanibuchi H (2012b) 2-Amino-3-methylimidazo[4, 5-f]quinoline (IQ) promotes mouse hepatocarcinogenesis by activating transforming growth factor-beta and Wnt/beta-catenin signaling pathways. Toxicol Sci 125(2):392-400. doi: 10.1093/toxsci/kfr314
42. Yamazaki K, Masugi Y, Sakamoto M (2011) Molecular pathogenesis of hepatocellular carcinoma: altering transforming growth factor-beta signaling in hepatocarcinogenesis. Dig Dis 29(3):284-288. doi: 10.1159/000327560
43. Yin XF, Chen J, Mao W, Wang YH, Chen MH (2012) A selective aryl hydrocarbon receptor modulator 3, 3′-Diindolylmethane inhibits gastric cancer cell growth. J Exp Clin Cancer Res 31:46. doi: 10.1186/1756-9966-31-46
44. Zhang S, Kim K, Jin UH, Pfent C, Cao H, Amendt B, Liu X, Wilson-Robles H, Safe S (2012) Aryl hydrocarbon receptor agonists induce microRNA-335 expression and inhibit lung metastasis of estrogen receptor negative breast cancer cells. Mol Cancer Ther 11(1):108-118. doi: 10.1158/1535-7163.MCT-11-0548
45. Zhao S, Kanno Y, Nakayama M, Makimura M, Ohara S, Inouye Y (2012) Activation of the aryl hydrocarbon receptor represses mammosphere formation in MCF-7 cells. Cancer Lett 317(2):192-198. doi: 10.1016/j.canlet.2011.11.025
46. Zollner G, Wagner M, Trauner M (2010) Nuclear receptors as drug targets in cholestasis and drug-induced hepatotoxicity. Pharmacol Ther 126(3):228-243. doi: 10.1016/j.pharmthera.2010.03.005